Skip to main content
. 2017 Feb 17;7(2):e527. doi: 10.1038/bcj.2017.8

Figure 6.

Figure 6

PTC596 attenuates AML growth in vivo. (a) NSG mice were injected intravenously with MOLM-13 cells and were randomized into PTC596- and vehicle-treated groups. Leukemia burden expressed as percent human CD45+ cells is shown in peripheral blood (PB) on day 13 after treatment initiation. In one vehicle-treated mouse, PB was collected on day 11 as it became moribund (open circle). (b) Survival of MOLM-13 xenograft mice after treatment with PTC596 or vehicle control. Survival comparison was made with log-rank test.